# A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

> **NCT03129100** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 773 (actual)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03129100
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-09
- **Primary completion:** 2020-05-26
- **Final completion:** 2021-05-27
- **Target enrollment:** 773 (ACTUAL)
- **Last updated:** 2022-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03129100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03129100, "A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03129100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*